A nutraceutical or functional-food company’s real technical problem usually isn’t the formula on paper, it’s getting that formula to survive manufacturing, storage, and digestion intact, and then proving the claim on the label holds up.
Bioavailability, delivery, potency, and substantiation each carry genuine, IRC §41-qualifying uncertainty, and each is commonly under-documented because the work reads as formulation or regulatory affairs, not research.
As with any R&D claim, this work still has to clear the standard four-part test, permitted purpose, uncertainty, experimentation, technological basis, but the more useful lens for this industry is tracing where the uncertainty sits across the product’s life, from active ingredient to finished claim.
Where the Uncertainty Lives
The Formulation Itself
Before bioavailability or delivery even enter the picture, combining actives into a single supplement formulation routinely raises its own unresolved technical questions, and several of them stand as their own defensible business components rather than one generic “formulation” line item.
Multi-ingredient compatibility
Combining two or more actives in one product can trigger degradation, binding, or potency loss that doesn’t show up until they’re mixed, a mineral that blocks absorption of a co-formulated vitamin, or an acidic botanical extract that destabilizes a probiotic strain in the same capsule. Resolving that requires testing combinations and ratios against real degradation and interaction data, not just checking each ingredient’s individual spec sheet.
Dosage-form design and manufacturability
The same active can behave completely differently as a tablet, capsule, gummy, or powder stick, tableting compression can degrade a heat-sensitive compound, and a gummy matrix can trap moisture that a capsule wouldn’t. Determining a workable dosage form is its own iterative technical problem, distinct from the ingredient science itself.
Excipient and carrier selection
Binders, fillers, and flow agents aren’t inert from a manufacturing standpoint, the wrong excipient can affect disintegration time, moisture uptake, or long-term stability. Testing excipient combinations against those outcomes is a distinct qualifying effort in supplement R&D, even when the excipients themselves are common, off-the-shelf materials.
Dose uniformity at scale
For potent or low-dose actives, ensuring the active is evenly distributed batch to batch, rather than clumping or settling during mixing, is a measurable process problem, particularly as a formulation moves from lab-scale mixing to full production blending equipment.
One caution here: work aimed purely at masking taste, smell, or mouthfeel to make a product more palatable falls under the same subjective-preference exclusion that applies across food and supplement R&D.
The line is the same one that applies industry-wide, testing why an ingredient combination physically destabilizes, discolors, or degrades is qualifying; testing which version a panel prefers is not.
Beyond the Base Formula
Bioavailability & delivery systems
Many actives degrade or pass through the body unabsorbed in their raw form. Developing an advanced supplement delivery mechanism, liposomal, nanoemulsion, or a novel carrier, to get meaningfully more of the active ingredient absorbed is a genuine, unresolved technical problem, not a formulation tweak.
Encapsulation
Protecting a sensitive compound (a live culture, an oxidation-prone oil, a light-sensitive vitamin) through manufacturing, storage, and gastric transit requires testing carrier materials and coating methods against real degradation data, not just picking one off a supplier’s spec sheet.
Stability & potency
Proving a stated potency holds for the labeled shelf life, across real storage conditions, is an accelerated- and real-time-testing problem with a measurable, non-subjective outcome.
Qualifying Activities
- Multi-ingredient compatibility and interaction testing across actives, excipients, and carriers
- Dosage-form development and manufacturability testing, tableting, encapsulation, gummy matrices, powder flow
- Excipient and carrier selection for stability, disintegration, and manufacturability
- Dose-uniformity testing through scale-up from lab mixing to production blending
- Delivery-system and carrier development, liposomal, nanoemulsion, matrix, or novel encapsulation formats
- Bioavailability and absorption testing against real physiological or in-vitro digestion models
- Potency and stability testing across real storage conditions and shelf-life claims
Bottom Line
If you’re developing a delivery system, proving stability and potency, or running your own substantiation trial, you’re likely generating qualifying R&D well beyond the formulation itself, provided the contracts and documentation support who actually bears the research risk.